169 related articles for article (PubMed ID: 36028965)
1. RON Receptor Tyrosine Kinase in Tumorigenic Stemness as a Therapeutic Target of Antibody-drug Conjugates for Eradication of Triple-negative Breast Cancer Stem Cells.
Suthe SR; Yao HP; Weng TH; Wang MH
Curr Cancer Drug Targets; 2023; 23(2):103-117. PubMed ID: 36028965
[TBL] [Abstract][Full Text] [Related]
2. RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE.
Suthe SR; Yao HP; Weng TH; Hu CY; Feng L; Wu ZG; Wang MH
Mol Cancer Ther; 2018 Dec; 17(12):2654-2664. PubMed ID: 30275241
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.
Yao HP; Feng L; Weng TH; Hu CY; Suthe SR; Mostofa AGM; Chen LH; Wu ZG; Wang WL; Wang MH
Mol Pharm; 2018 Aug; 15(8):3260-3271. PubMed ID: 29944378
[TBL] [Abstract][Full Text] [Related]
5. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer.
Feng L; Yao HP; Zhou YQ; Zhou J; Zhang R; Wang MH
J Exp Clin Cancer Res; 2016 Apr; 35():70. PubMed ID: 27102688
[TBL] [Abstract][Full Text] [Related]
6. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy.
Tong XM; Feng L; Suthe SR; Weng TH; Hu CY; Liu YZ; Wu ZG; Wang MH; Yao HP
J Immunother Cancer; 2019 Sep; 7(1):250. PubMed ID: 31519211
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy.
Feng L; Yao HP; Wang W; Zhou YQ; Zhou J; Zhang R; Wang MH
Clin Cancer Res; 2014 Dec; 20(23):6045-58. PubMed ID: 25294907
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibody (mAb)-induced down-regulation of RON receptor tyrosine kinase diminishes tumorigenic activities of colon cancer cells.
Li Z; Yao H; Guin S; Padhye SS; Zhou YQ; Wang MH
Int J Oncol; 2010 Aug; 37(2):473-82. PubMed ID: 20596675
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment.
Yao HP; Feng L; Zhou JW; Zhang RW; Wang MH
Am J Cancer Res; 2016; 6(5):937-56. PubMed ID: 27293990
[TBL] [Abstract][Full Text] [Related]
11. Antibody-drug conjugates targeting RON receptor tyrosine kinase as a novel strategy for treatment of triple-negative breast cancer.
Yao HP; Suthe SR; Hudson R; Wang MH
Drug Discov Today; 2020 Jul; 25(7):1160-1173. PubMed ID: 32479905
[TBL] [Abstract][Full Text] [Related]
12. RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.
Weng TH; Yao MY; Xu XM; Hu CY; Yao SH; Liu YZ; Wu ZG; Tang TM; Fu PF; Wang MH; Yao HP
Cancer Res Treat; 2020 Jul; 52(3):973-986. PubMed ID: 32324988
[TBL] [Abstract][Full Text] [Related]
13. RON receptor tyrosine kinase as a target for delivery of chemodrugs by antibody directed pathway for cancer cell cytotoxicity.
Guin S; Yao HP; Wang MH
Mol Pharm; 2010 Apr; 7(2):386-97. PubMed ID: 20039696
[TBL] [Abstract][Full Text] [Related]
14. The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells.
Yao HP; Zhou YQ; Ma Q; Guin S; Padhye SS; Zhang RW; Wang MH
Mol Cancer; 2011 Jul; 10():82. PubMed ID: 21749705
[TBL] [Abstract][Full Text] [Related]
15. Sustained expression of the RON receptor tyrosine kinase by pancreatic cancer stem cells as a potential targeting moiety for antibody-directed chemotherapeutics.
Padhye SS; Guin S; Yao HP; Zhou YQ; Zhang R; Wang MH
Mol Pharm; 2011 Dec; 8(6):2310-9. PubMed ID: 22014215
[TBL] [Abstract][Full Text] [Related]
16. Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase.
Yao HP; Luo YL; Feng L; Cheng LF; Lu Y; Li W; Wang MH
Cancer Biol Ther; 2006 Sep; 5(9):1179-86. PubMed ID: 16880737
[TBL] [Abstract][Full Text] [Related]
17. Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase.
Guin S; Ma Q; Padhye S; Zhou YQ; Yao HP; Wang MH
Cancer Chemother Pharmacol; 2011 May; 67(5):1073-83. PubMed ID: 20658288
[TBL] [Abstract][Full Text] [Related]
18. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
[TBL] [Abstract][Full Text] [Related]
19. Tetrandrine Inhibits Cancer Stem Cell Characteristics and Epithelial to Mesenchymal Transition in Triple-Negative Breast Cancer via SOD1/ROS Signaling Pathway.
Liu T; Li K; Zhang Z; Peng J; Yang J; Law BYK; Liu X; Li W
Am J Chin Med; 2023; 51(2):425-444. PubMed ID: 36692485
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]